Cargando…

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics

Major depressive disorder (MDD) is a heterogeneous disease. Efforts to identify biomarkers for sub-classifying MDD and antidepressant therapy by genome-wide association studies (GWAS) alone have generally yielded disappointing results. We applied a metabolomics-informed genomic research strategy to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Duan, Ray, Balmiki, Neavin, Drew R., Zhang, Jiabin, Athreya, Arjun P., Biernacka, Joanna M., Bobo, William V., Hall-Flavin, Daniel K., Skime, Michelle K., Zhu, Hongjie, Jenkins, Gregory D., Batzler, Anthony, Kalari, Krishna R., Boakye-Agyeman, Felix, Matson, Wayne R., Bhasin, Swati S., Mushiroda, Taisei, Nakamura, Yusuke, Kubo, Michiaki, Iyer, Ravishankar K., Wang, Liewei, Frye, Mark A., Kaddurah-Daouk, Rima, Weinshilboum, Richard M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802574/ https://www.ncbi.nlm.nih.gov/pubmed/29317604 http://dx.doi.org/10.1038/s41398-017-0056-8

Ejemplares similares

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication
por: Athreya, Arjun P., et al.
Publicado: (2019)

Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings
por: Athreya, Arjun P., et al.
Publicado: (2021)

Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication
por: Joyce, Jeremiah B., et al.
Publicado: (2021)

Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder
por: Grant, Caroline W., et al.
Publicado: (2022)

The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases
por: Neavin, Drew R., et al.
Publicado: (2018)

Model-based unsupervised learning informs metformin-induced cell-migration inhibition through an AMPK-independent mechanism in breast cancer
por: Athreya, Arjun P., et al.
Publicado: (2017)

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers
por: Li, Liang, et al.
Publicado: (2009)

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Qin, Sisi, et al.
Publicado: (2019)

ERICH3: vesicular association and antidepressant treatment response
por: Liu, Duan, et al.
Publicado: (2020)

Identification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs)
por: Tong, Yin, et al.
Publicado: (2015)

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Amare, Azmeraw T., et al.
Publicado: (2018)

TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
por: Ho, Ming-Fen, et al.
Publicado: (2020)

Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis
por: Breitenstein, Matthew K., et al.
Publicado: (2015)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
por: Biernacka, J M, et al.
Publicado: (2015)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
por: Biernacka, J M, et al.
Publicado: (2016)

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
por: Ji, Yuan, et al.
Publicado: (2012)

Single Nucleotide Polymorphisms at a Distance from Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand–Dependent Gene Expression
por: Neavin, Drew R., et al.
Publicado: (2019)

Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis
por: Yao, Jeffrey K., et al.
Publicado: (2013)

SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function
por: Zhang, Lingxin, et al.
Publicado: (2021)

Metabolic Profiling of Patients with Schizophrenia
por: Kaddurah-Daouk, Rima
Publicado: (2006)

Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
por: Liu, Mohan, et al.
Publicado: (2012)

Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines
por: Li, Liang, et al.
Publicado: (2014)

Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate
por: Karpyak, V M, et al.
Publicado: (2014)

Copy number variation and cytidine analogue cytotoxicity: A genome-wide association approach
por: Kalari, Krishna R, et al.
Publicado: (2010)

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment
por: Bhattacharyya, Sudeepa, et al.
Publicado: (2019)

Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
por: Kaddurah-Daouk, R, et al.
Publicado: (2011)

Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naïve Patients with Schizophrenia
por: Yao, Jeffrey K., et al.
Publicado: (2010)

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1
por: Cairns, Junmei, et al.
Publicado: (2019)

CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants
por: Zhang, Lingxin, et al.
Publicado: (2020)

Personalizing carbamazepine therapy
por: Mushiroda, Taisei, et al.
Publicado: (2011)

Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
por: Ho, Ming‐Fen, et al.
Publicado: (2022)

Detecting Associations between Major Depressive Disorder Treatment and Essential Hypertension using Electronic Health Records
por: Pathak, Jyotishman, et al.
Publicado: (2014)

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2021)

Associations between Purine Metabolites and Clinical Symptoms in Schizophrenia
por: Yao, Jeffrey K., et al.
Publicado: (2012)

Metformin Pharmacogenomics: Biomarkers to Mechanisms
por: Wang, Liewei, et al.
Publicado: (2014)

Pharmacogenomics in Practice
por: Wang, Liewei, et al.
Publicado: (2019)

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study
por: Biernacka, Joanna M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sfd3l1emtf7rl1oe05vgofrhcq